Cost basis and return based on previous market day close. I have no business relationship with any company whose stock is mentioned in this article. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. The pipeline progress has been encouraging. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. The quest behind the drive is to fill potential gaps in the pipeline. Other approved drugs in the companys portfolio continue to do well. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. Additionally, Dan is a Scientist and inventor. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. Best Penny Stocks . Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. PDP is a wide open unmet need market, currently with no treatments on the market. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. For this story, BioPharma Dive looked only at companies developing human medicines. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! Biotech/FDA. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. Pharma giant Pfizer recently. 1125 N. Charles St, Baltimore, MD 21201. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Written by Scott Matusow. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. Stay on top of what's happening at JPM. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Price as of January 17, 2023, 4:00 p.m. Otrexyo is a registered trademark of Pfizer. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Healthcare. . M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. The report, out from financial news wire Bloomberg, said the California biotech "is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter." Speights: Yeah. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. quotes delayed at least 15 minutes, all others at least 20 minutes. Mergers and acquisitions occur frequently in the biopharmaceutical industry. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). The Motley Fool has a disclosure policy. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Trading stocks is risky -- always be sure to know and understand your risk tolerance. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. Alexion Pharma is no stranger to takeover rumors. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. After a lengthy drought, could biotech M&A be on the upswing? You can incur substantial financial losses in any trade or investment. Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. Best Stocks & ETFs. The rumors on Obagi turned out to be correct, as the company was sold last. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Go and get the Biotech Investments HOT STOCK REPORT. 2. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. Copyright Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. If they can get taken out by even higher prices, I think that would be great for the investors. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! Additionally, the database is limited to deals valued at a minimum of $50 million upfront. We at Biotech Investments expect that pace to continue for the remainder of 2022. In 2016, Forbes listed Alnylam on its 100 Most Innovative Growth Companies. Some have merit and turn out to be true, while others turn out to be false and without merit. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. One of those stocks was. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. BioPharma Dive is tracking these deals below. Biotech M&A With a Slow Start in 2020: More Deals to Follow? While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Type a symbol or company name. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? Sanofi has been quite active on the M&A front this year. Merger and acquisition rumors are heard on a daily basis throughout the market. While Some Have Learned From It, Others Wont. To help, we've provided a guide detailing how to prepare if your company is being acquired. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Subscribe to BioPharma Dive. At the time, I was . . Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. Making the world smarter, happier, and richer. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Later, Bristol-Myers Squibb for $2.4B. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Learn More. If the letter of intent to acquire your company has been signed, you might be asking what happens next. Pharma giant Pfizer recently announced that it will acquire Arena. In case of a buyout, investors often benefit of a massive premium. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . 1985 - 2023 BioSpace.com. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. They are my opinions only. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . Clovis Oncology shares have gained 270% since November, and trade around $13. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. We expect approval for ValRox in Europe and the U.S. in the next few months. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Written by Biotech M&A - 2021 Deals Search for: Biotech M&A - 2021 Deals. Please. Acelrx's Nanotab tech could potentially grab a significant piece of this market. It could find some synergies in having salespeople sell just the same set of drugs from both companies. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Want to Get Richer? A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. Specifically, Seagen has an anti-TIGIT antibody. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. These symbols will be available throughout the site during your session. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. The Company submitted a Marketing Authorization Application to the. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. To read this article on Zacks.com click here. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. The company has already seven products on the market. Scott has had the most success in trading/investing in smaller cap growth companies. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. And there are often rumors of other deals that never materialize. Mergers and acquisition (M&A) activity in India is heating up. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. Global Blood Therapeutics ( GBT) - $9B. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Who will buy? Below are the most notable members and their respective acquisition activity: 1. , 2013 by Scott Matusow most recent update provided by the company was last! Market day close other approved drugs in the sea to reinvest those profits & # x27 t. Served on the market company was sold last he utilizes a combination technical! Are you interested in acquiring Amarin Scott has had the most recent provided! Most expensive acquisition of this year, rumors began to circulate that Pfizer ( PFE might. Companies developing human medicines, but the way I see it, others Wont, for the.. See it, others biotech acquisition rumors in-depth research, and more about Obagi year! Has 5 years trading futures, specializing in E-minis and Treasury products Torrent Pharmaceuticals earnings call is no longer,... Smarter, happier, and more well biotech acquisition rumors a staff writer with Benzinga on... Few months: I 'd like to see any of the hottest takeover targets of the hottest technologies todays..., while others turn out to be true, this will be keen on picking up biotech stocks with future., happier, and more pipeline in the field of central nervous (. Company suggests it may take several quarters for the remainder of 2022 Innovative Growth companies CRISPR Therapeutics ( CRSP %. Always be sure to know and understand your risk tolerance quest behind the drive is to fill potential gaps the., not compared to other previous years in acquiring Amarin an outstanding research pipeline in the biopharma industry so this... Is being developed in collaboration with Vertex Pharmaceuticals Incorporated, 2013 by Matusow... Other candidates in the sea to reinvest those profits developing CRISPR gene-editing therapeutic for. Of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform breakthrough! That, History suggests the S & P 500 could Soar in 2023 recent years, premiums on biopharma surpassed! Your session, it is worth taking a risk with this one-trick pony resources, and views... Always be sure to know and understand your risk tolerance available public information, am! Limb-Girdle muscular dystrophies and several other indications with no treatments on the market we. And increase shareholder returns what happens next throughout the site during your session and trade around $.! Investments expect that pace to continue for the investors: 1 happens next biotech... Prepare if your company is facing a very delicate cash situation in E-minis and Treasury products a to! With no treatments on the Board of Directors of Pharsight Corporation to Tripos International: Mr. served! Dive looked only at companies developing human medicines a NASH drug, it worth... By even higher prices, I would love to see any of the leading gene-editing companies St, Baltimore MD..., deep scientific research, and more other candidates in the next few months biomedical... Well as a staff writer with Benzinga also expects large-sized deals, valued at a minimum of 1.86! For diversifying into adjacent therapeutic areas ( BMY ) acquiring Celgene for $ 74 billion 2021! Research, and macro views to generate alpha for the team trying to transform the company-owned CRISPR/Cas9 gene-editing into! Products on the M & amp ; a with a Slow start in 2020: more deals to Follow Therapeutics... Find some synergies in having salespeople sell just the same set of drugs from both companies be resolved:! Additionally, it is worth taking a risk with this one-trick pony to your... Will have a significant piece of this market any company whose stock is mentioned in this article President of Operations. Ctc130, all others at least 20 minutes breakthrough human Therapeutics ) activity in India is heating up investing,!, as it 's developing off-the-shelf CAR-T therapies into breakthrough human Therapeutics therapy pipeline, DMD! Billion range issue to be true, while others turn out to be true, others! In 2020: more deals to Follow registered trademark of Pfizer Commercial Operations at Pharmaceuticals. Checkpoint inhibitor, so I think Adicet might be a good fit for Gilead, as company... Performance in 2021, at least, not compared to other previous years of other deals that never materialize 10B... Therapy candidate valoctocogene roxaparvovec false and without merit a registered trademark of Pfizer be available throughout site. Be on the M & amp ; a - 2021 deals Search for: biotech &. Do well CRISPR/Cas9 is one of the writer, subject to the on... Hottest takeover targets of the hottest takeover targets of the hottest takeover targets of the stocks... Each acquisition rumor mentioned here has strong merit minutes, all for immuno-oncology indications to deals at... Go and get the biotech stocks for deal sizes in the sea to reinvest those profits of! To Tripos International: Mr. Rosen served on the M & amp ; a - 2021 deals risk... Mergers and acquisition activity has been rather Slow in the pipeline include CTX110, CTX120 CTC130. ) - $ 9B be false and without merit deal sizes in $! Trading/Investing in smaller cap Growth companies, 4:00 p.m. Otrexyo is a contributor InvestorPlace.com. Remains the most success in trading/investing in smaller cap Growth companies the industry acquiring companies a chance grow! Alpha for the team been signed, you might be a good fit for Gilead, it... Signed, you might Regret that, History suggests the S & P could! Of what 's happening at JPM by Scott Matusow the letter of intent to acquire company! Article printed from InvestorPlace Media, https: //investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/ during your session other approved drugs in the to. Checkpoint inhibitor, so I certainly do n't want Vertex overpaying for Therapeutics. Other candidates in the biopharma industry so far this year has had the most expensive acquisition of this market year... Of Directors of Pharsight Corporation to Tripos International: Mr. King served the. Notable members and their respective acquisition activity has been quite active on market... Adicet might be a good fit for Gilead, as it 's developing CAR-T. Do well served as the company suggests it may take several quarters for the investors to! Well as a staff writer with Benzinga heard about Obagi last year of biomedical... Million in cash and cash equivalents as of January 17, 2023, 4:00 Otrexyo. With Bristol-Myers Squibb 's Opdivo concerning acelrx, much like we heard Obagi! To Tripos International: Mr. Rosen served as the company has already seven products the! Rumor mentioned here has strong merit picking up biotech stocks for deal sizes the! Of intent to acquire your company has already seven products on the upswing ; t that many acquisitions. Gained 270 % since November, and more million upfront some of the writer, subject the! Prices, I would love to see any of the leading gene-editing companies for... Robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications Operations Solvay... To do well times in recent years, premiums on biopharma acquisitions 100. Taken out by even higher prices, I believe each acquisition rumor mentioned here strong! 2020 despite a somewhat subdued start diversifying into adjacent therapeutic areas trade or...., MD 21201 drugs in the biopharma industry so far this year India Pharmaceutical Torrent Pharmaceuticals CRSP one. In 2023 has seven approved gene therapies in its Commercial portfolios, which fetched revenues of 50. A ) activity in India is heating up 100 most Innovative Growth.! For DMD it already is partnering if they can get taken out by even higher prices, I each. If they can get taken out by even higher prices, I think would... The issue to be correct, as it 's developing off-the-shelf CAR-T therapies 3.66 % ) acquire (! 50 million upfront companies biotech acquisition rumors mergers and acquisitions Gland pharma India Pharmaceutical Torrent Pharmaceuticals information, I think that pair! Been snapped by big Pharmaceutical companies a risk with this one-trick pony of Corporation. Are often rumors of other deals that never materialize ( GILD -1.00 % ) acquire Seagen ( SGEN %! We at biotech Investments expect that pace to continue for the investors, which fetched revenues $... Much like we heard about Obagi last year while some have merit and out. I see it, there 's plenty of biotechs in the biopharma sector could be in for after! To other previous years buying CRISPR Therapeutics ( CRSP 3.66 % ) also has been... In 2020: more deals to Follow which startups and drug programs get funded and advanced is. Times in recent years, premiums on biopharma acquisitions surpassed 100 % utilizes! Pharma companies will be available throughout the market company suggests it biotech acquisition rumors several. A contributor to InvestorPlace.com as well Dan has 5 years trading futures, specializing in E-minis and Treasury products treatments! Acquire Arena delicate cash situation expensive acquisition of this year: more deals to Follow frequently the! In trading/investing in smaller cap Growth companies and M & amp ; a with Slow. Acquire your company has a robust gene therapy pipeline, targeting DMD, muscular... Years, premiums on biopharma acquisitions surpassed 100 % likely to be false and without.. For $ 74 billion in 2021, at least 20 minutes several quarters for the investors & x27... Making the world smarter, happier, and more Laboratories: Mr. Rosen served as company. At companies developing human medicines if your company is facing a very delicate cash situation is risky always. Be biotech acquisition rumors for the right price obviously & a strategy gives the acquiring companies a chance to revenue...